Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention

The BCR::ABL1 gene fusion initiates chronic myeloid leukemia (CML); however, evidence has accumulated from studies of highly selected cohorts that variants in other cancer-related genes are associated with treatment failure. Nevertheless, the true incidence and impact of additional genetic abnormali...

Descripción completa

Detalles Bibliográficos
Autores principales: Shanmuganathan, Naranie, Wadham, Carol, Shahrin, NurHezrin, Feng, Jinghua, Thomson, Daniel, Wang, Paul, Saunders, Verity, Kok, Chung Hoow, King, Rob M., Kenyon, Rosalie R., Lin, Ming, Pagani, Ilaria S., Ross, David M., Yong, Agnes S.M., Grigg, Andrew P., Mills, Anthony K., Schwarer, Anthony P., Braley, Jodi, Altamura, Haley, Yeung, David T., Scott, Hamish S., Schreiber, Andreas W., Hughes, Timothy P., Branford, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Chronic Myeloid Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483360/
https://www.ncbi.nlm.nih.gov/pubmed/36951160
http://dx.doi.org/10.3324/haematol.2022.282184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483360/
https://www.ncbi.nlm.nih.gov/pubmed/36951160
http://dx.doi.org/10.3324/haematol.2022.282184

Ejemplares similares